September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Treat-and-Extend Regimen using Ranibizumab for Polypoidal Choroidal Vasculopathy: One Year Results
Author Affiliations & Notes
  • Seok Jae Lee
    Pusan national university hospital, Busan, Korea (the Republic of)
  • Kang Yeun Pak
    Pusan national university hospital, Busan, Korea (the Republic of)
  • Sung Who Park
    Pusan national university hospital, Busan, Korea (the Republic of)
  • Ik Soo Byon
    Pusan national university hospital, Busan, Korea (the Republic of)
  • Ji Eun E Lee
    Pusan national university hospital, Busan, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Seok Jae Lee, None; Kang Yeun Pak, None; Sung Who Park, None; Ik Soo Byon, None; Ji Eun Lee, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 510. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Seok Jae Lee, Kang Yeun Pak, Sung Who Park, Ik Soo Byon, Ji Eun E Lee; Treat-and-Extend Regimen using Ranibizumab for Polypoidal Choroidal Vasculopathy: One Year Results. Invest. Ophthalmol. Vis. Sci. 2016;57(12):510.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Clinical efficacy of treat-and-extend regimen (TER) has been reported in patients with exudative age-related macular degeneration. However, the clinical outcomes of a TER to treat polypoidal choroidal vasculopathy (PCV) have not yet been reported. We performed retrospective review study to investigate the efficacy of TER using ranibizumab to treat PCV.

Methods : We retrospectively reviewed the medical records of patients with PCV who had been treated using a TER for 1 year. Primary outcome was the proportion of eyes that did not lose ≥ 3 best-corrected visual acuity (BCVA) lines. Secondary outcomes included BCVA, central subfield macular thickness (CSMT), the number of intravitreal injections, the number of recurrences, and the maximal treatment interval without recurrence.

Results : The mean visual acuity improved from 0.69 ± 0.49 logMAR at baseline to 0.42 ± 0.37 logMAR at 3 months (P = 0.001), 0.40 ± 0.39 logMAR at 6 months (P = 0.001) and 0.33 ± 0.32 logMAR at 12 months (P < 0.001). The mean CSMT improved from 324.3 ± 90.7 µm at baseline to 236.4 ± 43.1 µm at 3 months (P < 0.001), 238.7 ± 77.6 µm at 6 months (P = 0.001), and 266.2 ± 99.3 µm at 12 months (P = 0.011). None of the subjects lost ≥ 3 lines, and 12 eyes (52.2%) gained ≥ 3 lines. The mean number of intravitreal injections was 7.4. The mean maximal treatment interval was 8.6 weeks. After the loading phase, 7 eyes (30.4%) showed no recurrence at treatment interval of 12 weeks. Six eyes (26.1%) demonstrated persistent disease activity for 12 months.

Conclusions : The TER effectively improved visual acuity in PCV while reducing the number of injections required.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×